REG - Allergy Therapeutics - Block Listing Interim Review

Allergy TherapeuticsAnnouncement

02/10/2023 18:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231002:nRSB4374Oa&default-theme=true

RNS Number : 4374O  Allergy Therapeutics PLC  02 October 2023

 

Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

 

Extension of Block Admission

 

Block Listing Interim Review

 

2 October 2023 Allergy Therapeutics plc (AIM: AGY) announces that an
application has been made to the London Stock Exchange for a block admission
of 5,000,000 ordinary shares of 0.1 pence each in the Company ("Ordinary
Shares") to be admitted to trading on AIM.

The Ordinary Shares may be issued pursuant to the exercise of share options
under Allergy Therapeutics plc 2013 Long Term Incentive Plan and will, upon
issue, rank pari passu in all respects with the Company's existing Ordinary
Shares. Following this increase, the total Block Listing will consist of
12,013,147 Ordinary Shares.

It is expected that admission will become effective on 5 October 2023. When
issued, the Ordinary Shares will rank pari passu with the existing ordinary
shares of the Company.

 

Block Listing Interim Review

 

 Name of applicant:                                                                ALLERGY THERAPEUTICS PLC
 Name of scheme:                                                                   Allergy Therapeutics plc 2013 Long Term Incentive Plan
 Period of return:                        From:                                    1 March 2023                To:                         30 September 2023
 Number and class of share(s) (amount of stock / debt securities) originally       10,000,000 ordinary shares of 0.1p each in the Company admitted to trading on
 listed and the date of admission:                                                 24 November 2017

                                                                                   Additional listing of 7,000,000 ordinary shares of 0.1p each in the Company
                                                                                   admitted to trading on 7 April 2021
 Balance of unallotted securities under scheme(s) from previous return:            7,013,772 ordinary shares*
 Plus:  The amount by which the block scheme(s) has been increased since the       Nil
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period:        Nil
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        7,013,772 ordinary shares

 

 Name of contact:              Karley Cheesman
 Telephone number of contact:  +44 (0) 1903 844 700

*The balance of unallotted securities under the scheme from the previous
return has been updated to account for 105,625 ordinary shares that were
issued during the previous review period.

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Panmure Gordon (Nominated Adviser and Broker)

Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0)20 7886 2500

 

Consilium Strategic Communications

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLREAKEAELXDFFA